Clinical Report: Single-cell eQTL Analysis of PRKCB–CTSL in Rheumatoid Arthritis

Overview

The article describes an integrated approach combining cell-type-specific cis-eQTLs and rheumatoid arthritis (RA) GWAS data with transcriptomic, network, machine-learning, single-cell, computational, and experimental analyses. It identifies a monocyte-linked PRKCB–CTSL pathway as a potential regulatory mechanism and therapeutic target in RA. The supplied material does not provide numerical results or details of experimental validation.

Background

RA is a chronic autoimmune disease associated with persistent synovial inflammation, joint damage, and systemic immune dysregulation. Its heterogeneous pathogenesis involves genetic susceptibility, immune-cell activation, transcriptional programs, and inflammatory signaling. Bulk transcriptomics can identify disease-associated signatures but may be affected by changes in cellular composition, whereas single-cell RNA sequencing resolves cell states without directly establishing inherited genetic regulation. The article frames cell-specific eQTL integration with GWAS and independent molecular evidence as a way to prioritize candidate regulatory genes.

Data Highlights

The supplied article context reports analysis of cell-type-specific cis-eQTLs across 17 immune-cell populations integrated with RA GWAS data. It does not provide effect estimates, sample sizes, statistical significance values, or other numerical results suitable for tabulation.

Key Findings

• The study integrated cis-eQTL data from 17 immune-cell populations with RA GWAS data to prioritize RA-associated eGenes.
• Transcriptomic, WGCNA, and machine-learning analyses were used to identify candidate targets after genetic prioritization.
• The article title identifies a monocyte-linked PRKCB–CTSL pathway as a potential regulatory mechanism and therapeutic target in RA.
• The stated framework also incorporates single-cell expression profiles, computational perturbation, and experimental validation; specific results from these components are not included in the supplied context.
• The article distinguishes genetic prioritization from proof of cellular localization or functional relevance, noting the need to integrate independent transcriptomic and functional evidence.

Clinical Implications

The supplied material presents PRKCB–CTSL as a candidate pathway for further investigation, not as an established treatment target. It does not report clinical testing, treatment outcomes, or evidence supporting a change to current RA management.

Conclusion

The article uses an integrated genetic and transcriptomic framework to prioritize a monocyte-linked PRKCB–CTSL pathway in RA. The available context does not provide quantitative findings or sufficient detail to assess the strength of the evidence or clinical applicability.

Related Resources & Content

1. Clinical Rheumatology — Discovery of Gene Expression Biomarkers for Predicting Methotrexate Response in Rheumatoid Arthritis Patients
2. ASCO Publications — Effects of a multimodal TCR/BCR repertoire foundation model on blood RNA-seq–based prediction of severe adverse event risk and rheumatoid arthritis.
3. ASCO Publications — Effects of a multimodal TCR/BCR repertoire foundation model on blood RNA-seq–based prediction of severe adverse event risk and rheumatoid arthritis.
4. ASCO Publications — Effects of a multimodal TCR/BCR repertoire foundation model on blood RNA-seq–based prediction of severe adverse event risk and rheumatoid arthritis.
5. https://www.eular.org/document/download/1406/ec021a77-cdf3-4de3-ae72-57c1757db549/1325
6. Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis | New England Journal of Medicine
7. Single cell immunoprofile of synovial fluid in rheumatoid arthritis with TNF/JAK inhibitor treatment | Nature Communications